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Background: A limited body of research suggests that ongoing maintenance enteral nutrition (MEN) can be
beneficial in maintaining disease remission in Crohn’s Disease (CD). We aimed to assess how achievable MEN is and
whether it helps to prolong remission.
Methods: Patients newly diagnosed with CD in 2010 and 2011 who commenced exclusive enteral nutrition (EEN)
for 8 weeks were followed up for a year post diagnosis. All patients who took EEN were encouraged to continue
MEN post EEN. Data on azathioprine use was also collected. Categorical variables were compared using chi–square/
Fischer’s exact test. Medians were expressed along with complete data ranges.
Results: 59 patients (34 male, median age 11.07 years, range 2.5-16.33 years) were identified. 11/59 (18%) had a
poor response to EEN and were switched to steroids. 48/59 patients completed 8 weeks EEN and achieved clinical
remission/response. 46/48 patients received Modulen IBD®, 29/48 (60%) consumed EEN orally and 19/48 (40%) via
NGT. 15/48 (31%) patients were able to continue MEN post EEN completion. MEN was consumed for a mean of
10.8 months (range 4–14 months). 14/15 patients drank MEN and 1/15 had MEN via NGT. Remission rates at 1 year
in patients continuing MEN were 60% (9/15) compared to15% (2/13) in patients taking no treatment (p = 0.001) and
65% (13/20) in patients taking azathioprine (p = 0.14).
Conclusion: A sub group of patients can continue MEN as a maintenance treatment and this seems a useful
strategy, especially in those who are not commencing azathioprine.
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Crohn’s disease (CD) is characterised by patchy, trans-
mural inflammation, which may affect any part of the
gastro-intestinal tract from the mouth to the anus. It is a
lifelong condition with periods of remission or relapse.
The incidence of paediatric CD is rising, with a mean age
at diagnosis in childhood of 11.9 years [1]. Presentation in* Correspondence: hazel.duncan4@nhs.net
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unless otherwise stated.the paediatric population is often with a variety of
symptoms, abdominal pain is usually a prominent fea-
ture alongside persistent or recurrent diarrhoea with or
without blood. Other symptoms include; nocturnal stool-
ing, tenesmus, lethargy, anorexia and nausea as well as
growth delay, delayed puberty and malnutrition [2]. Due
to the diverse range of symptoms diagnosis can often be
delayed, with associated issues of poor growth and under-
nutrition for all patients as well as delayed puberty in the
adolescent patient group.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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sumption of normal growth and pubertal development,
prevention of relapse and complications as well as im-
provement in quality of life. The benefits of treatment
need to be balanced against potential side effects. Nutri-
tional therapy was first introduced as a treatment for
CD in the 1970’s, [3] and since then EEN has been
recognised in many centres as a first line treatment for
active paediatric CD [4-7]. EEN has been shown to im-
prove nutritional complications at diagnosis including
weight loss, improving inflammatory markers and pro-
moting mucosal healing [8].
Heuschkel et al. (2000) demonstrated that EEN was as
effective as corticosteroids at inducing remission in chil-
dren with CD, a finding replicated by an updated meta-
analysis in 2007 [7,8]. EEN also has the benefit of having
minimal side effects. Zachos et al. (2007) identified that
while corticosteriods are commonly used in the treatment
of adults with CD, their use in children has been met with
caution due to their adverse effects notably on growth and
bone mineral density [9].
After induction of remission in CD a strategic therapy
will be chosen for maintenance of remission; most
commonly, in the paediatric setting, azathioprine which
carries potential toxicity risks and requires significant
monitoring [10]. It is now felt that the role of EN may
not just be limited to inducing remission but can also
be used to maintain remission [11]. Nutritional support
is key in maintaining normal growth and decreasing
disease complications with minimal side effects from
medications. There has however been a limited amount
of research undertaken relating to EN as a maintenance
treatment for patients with CD with many of the stud-
ies having been in adults [12]. The Cochrane report on
Enteral Nutrition for Maintenance of Remission in CD
only identified two papers which met their criteria for
inclusion [13].
This study aimed to assess if MEN post induction of
remission with EEN is achievable and if it helps prolong




This study was carried out in a tertiary centre with all pa-
tients attending a specialist paediatric IBD clinic. All pa-
tients were diagnosed with Crohn’s disease using standard
diagnostic criteria [14,15]. Response to treatment was de-
fined by using a physician’s global assessment as described
in previous studies from our centre [5].
A prospectively maintained departmental database was
used to identify all children who had been diagnosed
with CD in 2010 and 2011. All of the patients with active
luminal CD who were commenced on EEN aiming tocomplete 8 weeks of treatment were included in the
study. Patients were treated with either Modulen IBD
(Nestle, Croydon, UK), Frebini Energy (Fresenius Kabi,
Runcorn, UK) which was used for a patient under 5 years
of age or Neocate Advance (SHS Nutricia, Liverpool,
UK) which was used for a patient with co-existent cow’s
milk protein intolerance.
All patients who responded to and completed 8 weeks
EEN orally were universally encouraged to continue a
smaller volume of maintenance enteral nutrition to main-
tain/optimise nutritional status as well as potentially pro-
viding a role in prolonging disease remission. Patients
were encouraged to take MEN orally however if a NGT
was insitu for the EEN course then it was often more
difficult for them to consider supplemental nutrition
post EEN. Patients were asked to take a volume of ap-
proximately 25% of their original EEN volumes although
there was variability in this amount based on individual
patient factors.
Data collection
Data was collected retrospectively from departmental
notes which included; date of diagnosis, type, volume
and route of EEN received, whether clinical remission
was achieved following EEN and whether the patient
continued to take MEN. Clinical response or remission
was determined using the physician’s global assessment.
For the patients who continued to take MEN the length
of treatment was documented. For all patients the date
of relapse was documented and where applicable the
date commencing azathioprine was also documented.
There were no patients requiring treatment with metho-
trexate or infliximab during the 1 year study period. Fol-
low up data was collected at the end of EEN period and
then 6 months and 1 year post diagnosis for all EEN pa-
tients, not just those who took MEN. Relapse was de-
fined as needing a further course of EEN or steroids
within the follow up period.
Categorical variables were compared using chi-square
test or Fischer’s exact test as appropriate. Statistical sig-
nificance was defined as p value below 0.05. As an audit
of clinical practice we have clarified previously from our
ethics committee that no formal ethical approval was
needed for this type of study.
Results
Patient population
Fifty-nine patients were diagnosed with CD over the two
year period (Figure 1). Thirty-four of these patients were
male. The median age at diagnosis was 11.07 years (range
2.5–16.33 years). Eleven (18%) patients were determined
as having a poor response to EEN and were therefore
switched to steroids during their initial EEN treatment
course. No further follow up data was collected on
59 patients diagnosed with CD
11 patients switched to steroids
48 patients achieved remission via EEN 
29 EEN via oral 19 EEN via NGT
14 MEN via oral 1 MEN via NGT
In Remission 13/14 1/1
at 6/12
In Remission 8/14 1/1
at 1 year (5 patients continued MEN) (1 patient continued MEN)
Figure 1 Patient overview and the overall clinical outcomes in 59 patients diagnosed with Crohn’s Disease split into those receiving
EEN orally vs EEN via NGT.
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patients received EEN orally whilst 19 (40%) received
their feeds via NGT. Forty-six (96%) received Modulen
IBD for their course of EEN with 1/48 receiving Frebini
Energy and 1/48 receiving Neocate Advance. All pa-
tients had achieved clinical remission/response at the
end of 8 weeks EEN.
Fifteen (31%) of patients who completed 8 weeks of
EEN were able to continue MEN (11 male, 4 female).
The median age of those continuing MEN was 12.08 years
(range 2.5-14.9 years) compared to those unable to
take MEN 11.75 years (range 2.5-15.91 years, p = ns).
The MEN was taken for a median of 10 months (range
4–12 months). All of the patients who started MEN
had taken EEN orally rather than by NGT except for
the patient on Neocate Advance. The majority of pa-
tients (66%) drank Modulen IBD with 4 patients (26%)
consuming Fortisip as MEN. The final patient received
Neocate Advance via NGT aiming to provide almost
full nutritional requirements due to the patient’s young
age, a severe oral aversion and suspected multiple aller-
gies which predated his diagnosis of IBD. There was
no clear benefit for patients in remission compared
with those who responded. Patients consumed varying
quantities of MEN depending on age and appetite.
Median volume of feed consumed was 400 ml (range
200-1000 ml) with a median energy intake of 400 calo-
ries (range 200–1000 calories) per day. We assessed thecompliance and volume of feeds taken from dietetic,
nursing and medical notes. Patients were offered tele-
phone and email support throughout the treatment and
therefore we hope to have optimised compliance how-
ever there was no specific objective way of validation.
Patients were split into 4 groups for analysis (see
Table 1), those taking azathioprine & MEN, MEN only,
azathioprine only and those on no active maintenance
treatment (9, 6, 20 & 13 patients respectively). The num-
ber of patients who remained in remission from com-
pleting EEN and remained in remission at 6 months and
1 year was assessed. At 6 months follow up, patients on
no treatment were significantly more likely to have re-
lapsed compared to the other 3 groups (2/13 cf. 30/35
respectively, p = <0.001). Comparing patients specifically
on MEN only to those on no treatment at 6 months pa-
tients on MEN were significantly more likely to remain
in remission (6/6 cf. 2/13 respectively, p = 0.003).
The remission rate in the MEN and azathioprine
group was three times as many as those in the no treat-
ment group (Table 1). Supplements were consumed for
a mean of 10.8 months but with only 33% of patients
still continuing to take MEN at time of relapse. Compar-
ing all patients on MEN with those on no MEN, patients
undertaking MEN were significantly more likely to be in
remission at 6 months but not at 1 year (MEN 14/15 cf.
no MEN 18/33, p = 0.02 at 6 months, MEN 9/15 cf. no
MEN 15/33, p = 0.53 at 1 year).
Table 1 Remission rates for different maintenance treatment over the 1st year of follow up







at 1 year(n = 48)
MEN & azathioprine 9 8/9 (89%) 0.23 6/9 (67%) 0.46
MEN no azathioprine 6 6/6 (100%) 0.16 3/6 (50%) 0.66
No MEN, no azathioprine 13 2/13 (15%) <0.001 2/13 (15%) 0.001
Azathioprine only 20 16/20 (80%) 0.18 13/20 (65%) 0.14
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This study summarises the use of MEN in paediatric CD
patients from a complete treatment cohort who have all
received EEN for induction of remission. The use of
MEN at follow up was then compared alongside the use
of azathioprine. The results from this study demonstrate
that MEN is a useful strategy to help maintain remis-
sion. MEN is a favourable option especially in patients
not taking azathioprine, but it’s uses are limited due to
issues of palatability and ‘taste fatigue’ in a proportion of
patients. Compliance can also be an issue potentially dis-
couraging patients from taking future courses of EEN,
however there is no specific research which has ad-
dressed this.
For many years immunosuppression has been used to
maintain remission in the majority of patients with CD
[16,17]. However these drugs have a recognised side ef-
fect profile [18]. This study provides further support for
the use of nutritional therapy in children with CD both
as an induction therapy but more specifically as a main-
tenance therapy. It has been well documented that EEN
is an effective and favourable treatment option for pa-
tients diagnosed with CD, however until now there has
only been a small amount of research looking at MEN
[5,6,19].
Hania et al. (2012) have conducted the only rando-
mised controlled trial comparing mercaptopurine (MP)
and elemental diet as maintenance treatment for CD
[20]. They studied 95 Japanese adult CD patients who
were in clinical remission who were split into 3 mainten-
ance groups (one group received MP, the second elem-
ental diet and the third no active treatment). Follow up
at 2 years demonstrated significantly higher remission in
both patients receiving MP (56.7%) and patients receiv-
ing elemental diet (46.9%) compared to the control group
(21.2%). Clearly this study has produced very similar
results to the current study. Of note Hanai et al. (2012)
had a longer follow up period, studied adult patients and
used an elemental rather than a polymeric feed. In
the study only 2/32 (6%) patients self-inserted an NG
tube to receive elemental feeds, the remaining patients
took supplemental drinks orally. The high numbers of
patients able to drink elemental diet for 2 years is not
something we think would be achievable in our clinical
practice.A Cochrane review identified two randomised control
trials of MEN which met the inclusion criteria [13] and
were both adult studies [21,22]. The study by Verma
et al. (2001) had a moderately small sample size (33 adult
patients who were steroid dependent) with no details
documented as to the route of obtaining remission [21].
Of these 19 patients took elemental supplements and 14
patients took polymeric supplements. The supplements
provided 35-50% of patient’s pre-trial calorie intake. Pa-
tients were followed up at 1 year and failure was deter-
mined as increase in Crohn’s disease activity index
(CDAI), inability to withdraw steroids or surgery being
required. 18% patients were unable to complete the study
due to tolerance issues. 43% patients achieved and main-
tained remission and had steroids withdrawn. They iden-
tified similar remission rates in the polymeric diet group
versus the elemental group. This study therefore demon-
strates that whole protein sip feeds, which are generally
more palatable, were effective at maintaining remission
within this patient group.
The more recent study by Takagi et al. (2006) had a larger
sample size of 51 and was carried out across two centres
[22]. Patients were randomly assigned to 2 groups, the
first group (n = 26) received half their nutritional re-
quirements as an elemental diet and the second group
(n = 25) had a free unrestricted diet with no nutritional
supplementation. Remission had initially been achieved
via surgery, 6–8 weeks EEN, IV methyl prednisolone or
Infliximab. All patients were commenced on mesalazine
and patients already on azathioprine prior to commen-
cing study remained on the medication. They used an
elemental diet providing 900-1200 ml and calories daily.
19% used an NG tube during the study period to obtain
the elemental diet. 35% patients in the elemental diet
group had relapsed by 2 years, compared to 64% in free
diet group. While these studies are on adult patients
using elemental feed the results are similar to our own.
This study demonstrates similar remission rates to other
studies using EEN as an induction treatment at diagnosis
of CD. A moderately high proportion of the patients re-
ceived the EEN via NGT but this rate was similar to previ-
ous work by our group [5,23] as well as others [24]. Our
centre has a strong multidisciplinary team (MDT) ap-
proach to patients undertaking EEN, with patients follow-
ing a formalised pathway with regular MDT support. A
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has been shown to improve our numbers of patient able
to complete 8 week courses of EEN [25]. Currently pa-
tients within our population group only managed to pro-
gress to MEN if they received EEN orally. Patients
undertaking NG feeds for EEN were unable to consume
MEN orally. However, patients were offered the same nu-
tritional formulation for MEN as they were given for EEN
which raises questions as to whether an alternative, poten-
tially more palatable nutritional drinks for the individual
patients could be used for maintenance. As such we now
offer patients who have taken EEN by NG tube an alterna-
tive type of supplemental feed to try for maintenance ther-
apy. We did not adopt an approach similar to Wilschanski
et al. (1996) where they continued NG nutritional support as
we felt this would be too difficult for patients to undertake
[11]. However with this study and the other supportive
data this may now be an option worth further exploration
in selected patients.
There have been a small number of MEN studies
within the paediatric population however these are non-
randomised, non-blinded and all retrospective (Table 2).
In our patient population 15/48 (31%) were able to con-
tinue MEN post achieving remission via EEN. These figures
were lower than those identified by Knight et al. (2005)
[26]. The number of patients able to continue MEN
in our study was comparable to Day et al. (2006) who
stated 31% of their patients continued maintenance sup-
plemental drinks [27]. The feeds used in their study var-
ied from elemental feeds to whole protein feeds and this







Verma et al. [21] 33 33 Oral
Adult population
Tageki et al. [22] 51 26 Oral/NG
Adult population
Wilschanski et al. [11] 47 28 NGT
Paediatric population
Knight et al. [26] 40 22 Oral
Paediatric population
Day et al. [27] 27 4 Oral
Paediatric population
Hanai et al. [20] 95 32 Oral/NG
Adults
Duncan et al. 48 15 Oral/NG
Paediatric population
*Relapse rates at 1.5 years.however do not define why certain feed choices were
made [11,21,26].
Contrary to the findings of our study and other pub-
lished work, Knight et al. (2005) reported that MEN
was not associated with a decreased relapse rate with
no significant difference found between the group re-
ceiving MEN and the control group [26]. Their study
focused on paediatric patients and the volumes of feeds
to be taken were large at 1000 ml. This was felt to lead
to issues with compliance and they documented that
volumes consumed were variable.
In our study, the number of patients in remission at
6 months was statistically significant, however at 1 year
was not. This could be due to patients stopping supple-
ments due to compliance and taste fatigue. Following on
from these results as a centre we feel it is important that
support is optimised and a defined patient pathway
would be beneficial to enhance compliance rates with
MEN; our clinical practice has changed accordingly.
All studies (Table 2) state the volume of supplemental
feeds consumed by patients; however it remains unclear
from the literature whether this directly affects remission
rates when using MEN. Early satiety and taste fatigue can
be problematic if volumes are too high, however it is im-
portant that volumes are adequate to promote treatment
efficacy. Taste fatigue is a commonly reported phenomenon
in patients with chronic disease who take oral supplements
[28]. This will limit the length of time supplements can be
taken for; methods to minimise taste fatigue include look-
ing at polymeric supplements which are often reported to
be more palatable [29].intenance of remission
Type of
supplementation
Volume taken Remission rates
at 1 year
19 elemental 35-50% EAR 8/19 elemental
14 polymeric 6/14 polymeric
Elemental 900-1200 ml/calories daily 9/29 elemental*
elemental or semi-
elemental feeds
50-60% EAR for 4 or 5 nights
per week overnight
17/28 (p < 0.02)
Elemental or polymeric 1 litre daily 9/22 (not
statistically sig)
polymeric formula 300-1800 ml daily 4/4
elemental >900 calories daily 20/32 (62.5%)
Polymeric or elemental 240-1000 ml 9/15
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understood. Several studies have shown that the gut
microbiota is changed significantly after a course of EEN
and once diet is introduced the gut flora reverts back to
a similar state as pre EEN [30,31]. This raises the
question-does MEN maintain the changes to gut micro-
biota and therefore maintain remission rates for longer?
The studies examining this are small but do support
the broad concept that MEN does seem to prolong a
favourable bacterial profile compared to standard diet.
There are limitations to our study; sample size is mod-
erate and all patients are from a single centre which has
a strong track record for supporting patients undergoing
EEN. The study is retrospective and non-randomised
but has achieved 100% patient ascertainment and follow
up over a 2 year period of all new diagnoses of CD. The
follow up time is relatively short but with a significant
fall off in patients managing to take supplements by this
time is likely to be adequate for analysis purposes for
this type of study.
Conclusion
In conclusion, this study demonstrates that a sub group
of patients can continue nutritional supplements post in-
duction of remission with EEN as a maintenance treat-
ment. This seems a useful strategy in a sub group of
patients especially in those who are not commencing
azathioprine. To our knowledge this is the first review
evaluating MEN and azathioprine as an ongoing treat-
ment option for this group in paediatrics. A randomised
controlled trial would be beneficial in helping to clarify
these provisional findings further.
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